FDA Inspectors Found Black Mold, Insects, and Discarded Samples at a Chinese Plant Making Semaglutide and Tirzepatide Ingredients for Compounding
FDA inspection reports obtained by Bloomberg through a Freedom of Information Act request describe black mold on equipment, "gross contamination" on floors, and "significant insect activity" in ceilings at Chengdu Shengnuo Biopharm in southwest China, inspected in August, where staff moved documents to lockers and poured product samples into sinks. A September inspection found that Nanjing Chengong Pharmaceutical had bought active ingredients from other factories and applied its own seal without reviewing their test data. FDA's Import Alert 66-40 lists Chengdu Shengnuo as of September 19, 2026 and Nanjing Chengong as of October 1, so their products can be detained at the U.S. border; the companies made semaglutide and tirzepatide ingredients used in compounded drugs.